文献速递神经免疫

家庭站立架方案对进展型多发性硬化患者的疗效与成本效果:SUMS实用多中心随机对照试验

Assessment of a home-based standing frame programme in people with progressive multiple sclerosis (SUMS): a pragmatic, multi-centre, randomised, controlled trial and cost-effectiveness analysis.
PubMed 文献 · Lancet Neurol · 2019-01-01

SUMS试验在英国8个中心纳入140例严重运动障碍的进展型多发性硬化患者,随机分为站立架方案+常规护理组与单纯常规护理组。

要点

  • 家庭站立架方案可显著改善严重进展型多发性硬化患者的运动功能,但幅度未达预设临床意义阈值。
  • 干预组短期肌肉骨骼疼痛报告频率高于对照组(41% vs 22%),但无严重不良事件。

核心结论

  • 家庭站立架方案显著提高严重进展型多发性硬化患者的AMCA运动功能评分,但未达到预设的9分临床意义阈值。
  • 该方案是首批在该人群中有效的物理治疗干预之一,可作为家庭自我管理方案在临床实践中常规实施。

研究设计与样本

  • SUMS为实用、多中心、随机对照优效性试验,在英国两个地区8个中心开展。
  • 共筛查285例进展型多发性硬化患者,随机分配140例至站立架组(n=71)或常规护理组(n=69)。
  • 主要临床结局为36周时AMCA评分,在改良意向治疗人群(122例完成主要结局评估)中分析。
  • 干预包括2次家庭物理治疗(每次60分钟)设置站立架方案,辅以6次电话随访(每次15分钟),要求每周站立30分钟、3次/周,持续20周。
  • 采用评估者盲法,在基线、20周和36周进行临床医生评定和患者自评。

主要发现

  • 患者日记收集的不良事件中,短期肌肉骨骼疼痛频率在站立架组为486/1188(41%),常规护理组为160/736(22%)。
  • 肌肉骨骼疼痛持续超过7天者共5例(站立架组2例,常规护理组3例)。
  • 无与研究相关的严重不良事件发生。

关键数值与推荐

  • 主要结局为36周时AMCA评分,预设9分变化为临床意义阈值。

临床怎么用

  • 对于严重运动障碍的进展型多发性硬化患者,可考虑提供家庭站立架方案作为自我管理干预。
  • 实施时需包含2次家庭物理治疗设置和6次电话随访支持。
  • 应告知患者短期肌肉骨骼疼痛可能增加,并监测持续超过7天的疼痛。

局限性

  • 运动功能改善未达预设的9分临床意义阈值。
  • 改良意向治疗分析仅纳入122例完成主要结局评估者,可能存在 attrition 偏倚。
  • 干预组短期肌肉骨骼疼痛报告频率高于对照组,可能与干预相关。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: People severely impaired with progressive multiple sclerosis spend much of their day sitting, with very few options to improve motor function. As a result, secondary physical and psychosocial complications can occur. Effective and feasible self-management strategies are needed to reduce sedentary behaviour and enhance motor function. In this study, we aimed to assess the clinical and cost effectiveness of a home-based, self-managed, standing frame programme. METHODS: SUMS was a pragmatic, multicentre, randomised controlled superiority trial of people with progressive multiple sclerosis and severe mobility impairment, undertaken in eight centres from two regions in the UK. The study had assessor-blinded outcome assessments with use of clinician-rated and patient-rated measures at baseline, 20 weeks, and 36 weeks. After baseline assessment, participants were randomised (1:1) by computer-generated assignment to either a standing frame programme plus usual care or usual care alone. The intervention consisted of two home-based physiotherapy sessions (60 min each) to set up the standing frame programme, supported by six follow-up telephone calls (15 min per call). Participants were asked to stand for 30 min, three times per week over 20 weeks, and encouraged to continue in the longer term, although no further physiotherapy support was provided. The primary clinical outcome was motor function measured by the Amended Motor Club Assessment (AMCA) score at week 36, analysed in the modified intention-to-treat population (excluding only patients who were deemed ineligible after randomisation, those who withdrew from the trial and were unwilling for their previously collected data to be used, or those who did not provide baseline and week 36 measurements). A 9-point AMCA score change was considered clinically meaningful a priori. Adverse events were collected through a daily preformatted patient diary throughout the 36 weeks and analysed in the modified intention-to-treat population. An economic assessment established the resources required to provide the standing frame programme, estimated intervention costs, and estimate cost effectiveness. This trial is registered with the International Standard Randomised Controlled Trials, number ISRCTN69614598. FINDINGS: Between Sept 16, 2015, and April 28, 2017, 285 people with progressive multiple sclerosis were screened for eligibility, and 140 were randomly assigned to either the standing frame group (n=71) or the usual care group (n=69). Of these, 122 completed the primary outcome assessment (61 participants in both groups) for the modified intention-to-treat analysis. The use of the standing frame resulted in a significant increase in AMCA score compared with that for usual care alone, with a fully adjusted between-group difference in AMCA score at 36 weeks of 4·7 points (95% CI 1·9-7·5; p=0·0014). For adverse events collected through patient diaries, we observed a disparity between the two groups in the frequency of short-term musculoskeletal pain (486 [41%] of 1188 adverse events in the standing frame group vs 160 [22%] of 736 adverse events in the usual care group), which was potentially related to the intervention. The musculoskeletal pain lasted longer than 7 days in five participants (two in the standing frame group and three in the usual care group). No serious adverse events related to the study occurred. The standing frame group had a mean 0·018 (95% CI -0·014 to 0·051) additional quality-adjusted life-years (QALYs) compared with those of the usual care group, and the estimated incremental cost-per-QALY was approximately £14 700. INTERPRETATION: The standing frame programme significantly increased motor function in people with severe progressive multiple sclerosis, although not to the degree that was considered a priori as clinically meaningful. The standing frame is one of the first physiotherapy interventions to be effective in this population. We suggest that the programme is feasible as a home-based, self-managed intervention that could be routinely implemented in clinical practice in the UK. FUNDING: UK National Institute of Health Research.

来源:Lancet Neurol,查看原文。版权归原作者所有。

引用

  1. Freeman J, Hendrie W, Jarrett L, et al. Assessment of a home-based standing frame programme in people with progressive multiple sclerosis (SUMS): a pragmatic, multi-centre, randomised, controlled trial and cost-effectiveness analysis. Lancet Neurol. 2019. PMID: 31301748. doi:10.1016/S1474-4422(19)30190-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。